<DOC>
	<DOCNO>NCT01101542</DOCNO>
	<brief_summary>This Post Marketing Surveillance ( PMS ) collect safety data use GSK Biologicals ' human papillomavirus ( HPV ) vaccine local target population female per regulation Korean Food Drugs Administration ( KFDA ) .</brief_summary>
	<brief_title>Evaluation Safety Vaccine Against Cervical Cancer Healthy Korean Females</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Female subject age include , 10 25 year time first vaccination . Subjects investigator believe parents/guardians comply requirement protocol ( e.g. , completion diary card , return vaccination visit etc ) enrol PMS . Written inform consent obtain subject subject ' parent/ guardian . Subjects childbearing potential must pregnant . Absence pregnancy verify ( e.g . urine pregnancy test ) per investigator 's clinical judgement . Subjects contraindication accord local approve prescribe information . No previous administration HPV vaccine Cervarix® . No previous administration two dos Cervarix® . No planned administration HPV vaccine Cervarix® PMS</criteria>
	<gender>Female</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Post-marketing surveillance</keyword>
	<keyword>Human papillomavirus</keyword>
	<keyword>Korea</keyword>
	<keyword>Safety</keyword>
	<keyword>Prescribing Information</keyword>
</DOC>